Premium
Adriamycin plus alkylating agents in the treatment of metastatic breast cancer
Author(s) -
Lokich Jacob J.,
Skarin Arthur T.,
Mayer Robert J.,
Cr Henderson I. ÀIg,
Blum Ronald H.,
Frei Emil
Publication year - 1977
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197712)40:6<2801::aid-cncr2820400608>3.0.co;2-u
Subject(s) - medicine , cyclophosphamide , regimen , melphalan , metastatic breast cancer , methotrexate , fluorouracil , complete response , oncology , breast cancer , maintenance therapy , surgery , chemotherapy , cancer
A randomized trial of Adriamycin (A) in combination with melphalan (M), (MA therapy), and in combination with M plus cyclophosphamide (C) (MAC therapy), was initiated in 40 evaluable patients with metastatic breast cancer. Twenty‐two patients demonstrated an objective response to therapy: 9/20 to the MA regimen, and 13/20 to the MAC regimen. For the 22 responders, median duration of response is not yet achieved for either complete or partial responders, at 10 and 9 months, respectively. The addition of the two alkylating agents to Adriamycin was superior to the single alkylating agent addition, both in total response rate and in completeness of response. Maintenance therapy, after achieving the maximum cumulative dose of Adriamycin, was provided by cyclophosphamide plus methotrexate and 5‐fluorouracil (CMF). In 19 patients completing induction and entering maintenance therapy, only one relapse has developed with maximum follow‐up at 15 months. Cancer 40:2801‐2805, 1977.